==== Front JCO Precis Oncol JCO Precis Oncol po PO JCO Precision Oncology 2473-4284 Wolters Kluwer Health 37315262 PO.22.00693 10.1200/PO.22.00693 Case Reports Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review https://orcid.org/0000-0003-4393-2927 Ma Julie MD 1 Morimoto Kenji MD 2 https://orcid.org/0000-0003-3030-8420 Pulsipher Michael A. MD 3 Parekh Chintan MD 1 4 1 Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA 2 Department of Pediatrics, Kaiser Permanente Fontana Medical Center, Fontana, CA 3 Division of Pediatric Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 4 Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA Chintan Parekh, MD, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, 4650 Sunset Blvd, Mail Stop #54, Los Angeles, CA 90027; e-mail: cparekh@chla.usc.edu. 2023 14 6 2023 14 6 2023 7 e220069315 12 2022 24 3 2023 20 4 2023 © 2023 by American Society of Clinical Oncology 2023 American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/ OPEN-ACCESSTRUE ==== Body pmcIntroduction Fanconi anemia (FA), a genetic DNA damage repair (DDR) pathway deficiency, is the most common inherited bone marrow (BM) failure syndrome.1 Features of FA include chromosomal instability, congenital abnormalities, extreme sensitivity to DNA-damaging agents, and a predisposition for malignancy, particularly myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and solid tumors.2-4 Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) constitutes curative therapy for BM failure, MDS, and AML in FA,5 but importantly, the nonhematopoietic cells remain unable to repair DNA damage post-transplant.6 Typical intensive AML chemotherapy regimens carry an unacceptably high risk of toxicity in patients with FA, including prolonged myelosuppression and mucositis.7 FA-associated MDS/AML is treated with reduced intensity conditioning (RIC) HSCT preceded by no or limited chemotherapy because of the extreme sensitivity of FA cells to alkylating agents and radiation,5,8 higher rates of graft-versus-host disease,9,10 and predisposition to solid malignancies.10-12 Of note, given the presence of the FA DDR deficiency in the MDS/AML cells, FA-associated MDS/AML is sensitive to low-intensity chemotherapy.13 Donor cell–derived leukemia (DCL) is a complication of allo-HSCT where leukemia arises from donor cells after engraftment and has a poor prognosis.14-16 The etiology underlying DCL is likely multifactorial; proposed factors include germline mutations and rapid proliferation of donor cells, post-transplant immunocompromised state, and treatment damage to the BM microenvironment.14,16-18 A multiple-hit hypothesis where hematopoietic stem cells with a pre-existing defect are influenced by recipient- and transplant-related factors to transform into malignancy is supported by the lack of leukemogenesis in the donor in most cases.15-18 Here, we report a case of a child who developed donor-derived NPM1-mutated MDS/AML after HSCT for BM failure because of FA. Management of DCL in a patient with FA posed a unique challenge because of the need for a more effective approach than RIC without causing excessive toxicity. Since donor-derived myeloblasts would not be as sensitive to chemotherapy as the DDR-deficient blasts in FA-related MDS/AML, RIC alone would likely not induce a remission. However, intensive chemotherapy would be highly toxic in a patient in whom all the nonhematopoietic cells carried the FA defect. Therefore, she was treated with venetoclax/azacitidine, a regimen with minimal nonhematopoietic toxicity and low DNA damage potential known to induce high remission rates in NPM1-mutated AML, before a second RIC HSCT. The patient's guardian consented to the submission of the case report to the journal. Case Report A 5-year-old girl was diagnosed with FA after presenting with thrombocytopenia. BM showed hypocellularity (20%-40%) without dysplasia and normal cytogenetics. BM failure testing was negative for paroxysmal nocturnal hemoglobinuria (flow cytometry) with normal telomere lengths and serum adenosine deaminase levels. FA was diagnosed on the basis of abnormal chromosome breakage with diepoxybutane and mitomycin C and a compound heterozygous FANCA mutation (Table 1).2 TABLE 1. Fanconi Anemia Panel Demonstrating FANCA Genetic Mutations She underwent a 4/6 matched cord blood HSCT preceded by RIC with low-dose cyclophosphamide (10 mg/kg daily for 4 days), fludarabine (35 mg/m2 daily for 4 days), total body irradiation (300 cGy), and antithymocyte globulin (ATG). She experienced engraftment after 13 days with resolution of BM failure. Forty-five months after HSCT, she developed thrombocytopenia (9k/uL). BM showed myelodysplasia with 10% myeloblasts and 100% donor chimerism, consistent with DCL. NPM1, GATA1, and WT1 mutations were detected, indicative of donor-derived MDS/AML (Table 2).19,20 TABLE 2. Bone Marrow Aspirate Demonstrating Three Variants of Strong Clinical Significance From DNA Analysis of the OncoKids Cancer Panel Given the high risk of toxicity with DNA-damaging agents in FA and the high sensitivity of myeloblasts with the FA DDR defect, FA-related MDS/AML is typically treated with RIC HSCT without intensive chemotherapy before conditioning.21-25 However, in view of the blasts being of donor origin (ie, no chemotherapy-sensitizing FA DDR defect) and the planned use of RIC for a second HSCT, she was considered to be at high risk for post-transplant relapse without remission-inducing antileukemia therapy before conditioning. A pretransplant minimal residual disease (MRD)–negative remission is one of the strongest predictors of favorable outcomes for HSCT in AML.26 In AML, NPM1 mutations are strongly predictive of a high MRD-negative response rate (88%) with venetoclax/azacitidine therapy.27-29 Furthermore, the low DNA-damaging potential of venetoclax/azacitidine was favored given the exquisite sensitivity of the nonhematopoietic FA cells to DNA-damaging agents. Thus, the toxicity risks related to the FA DDR defect, chemotherapy mechanisms of action, and specific molecular profile of the MDS/AML drove the choice of venetoclax/azacitidine. Azacitidine was administered (75 mg/m2 dose once daily) for 1 week, and venetoclax was administered for 21 days instead of the typical 28 days to limit myelosuppression.30,31 The US Food and Drug Administration–approved adult dose of venetoclax with the recommended package insert reduction for concomitant posaconazole prophylaxis was used (Table 3).32-34 She was admitted for observation because of grade 4 neutropenia. After one course of venetoclax/azacitidine, she developed a subdural hematoma of unknown etiology (platelet count >100k/uL). She underwent craniotomy and evacuation; HSCT was delayed by 1 month. BM showed complete remission with MRD negativity by flow cytometry and NPM1 polymerase chain reaction (PCR). She subsequently contracted respiratory syncytial virus, necessitating a further 6-week delay of HSCT. Given the delay, an additional 14-day cycle of venetoclax/azacitidine was administered, a duration demonstrating similar efficacy and reduced myelosuppression relative to the conventional 28-day cycle in a study of elderly patients with AML.35 After the second cycle, the BM showed MRD negativity by flow cytometry; peripheral blood showed low level NPM1 PCR positivity (ratio of 0.0056). She then underwent RIC with low-dose cyclophosphamide, fludarabine, busulfan, and ATG followed by an 8/10 cord blood HSCT. BM was MRD-negative (flow cytometry and PCR) 3 months post-HSCT. She remains in remission over 1.5 years after HSCT. TABLE 3. Chemotherapy Regimen Administered Before Conditioning and Hematopoietic Cell Transplantation Discussion DCL is a rare complication of allo-HSCT and, to our knowledge, has not been reported in a host with FA.36 Because of its poor prognosis, our patient was thought to require more potent antileukemia therapy than RIC alone to maximize the probability of a pretransplant MRD-negative remission and thereby optimize the likelihood of a curative second RIC HSCT. Standard conditioning regimens yield exceedingly poor outcomes in FA.8 Thus, HSCT in FA is now performed with RIC regimens; these have resulted in improved outcomes and decreased toxicity.7 The high risk of toxicity precludes the use of intensive chemotherapy before HSCT conditioning in FA-related AML; chemotherapy before conditioning is limited to low-dose regimens.13,37,38 Hematologic malignancies highly express the antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL2).39 Venetoclax, a selective BCL2 inhibitor, counteracts BCL2-mediated cell survival.39 Azacitidine, a DNA hypomethylating agent, synergizes with venetoclax to induce apoptosis through NOXA, a proapoptotic protein.40 The combination of venetoclax with a hypomethylating agent has demonstrated promising outcomes without significant toxicity in MDS/AML (67% composite response rate [CRR, complete remission with or without count recovery], 29% MRD negativity rate).41,42 Of note, the presence of an NPM1 mutation is strongly predictive of response (91.5% CRR, odds ratio 5).41 Several laboratory studies have uncovered potential mechanisms by which mutant NPM1 increases sensitivity to venetoclax. NPM1-mutated AML cells show 20-fold higher sensitivity to venetoclax than NPM1 wild-type AML cells in vitro.43 HOX overexpression, a key leukemogenic mechanism in NPM1-mutated cells,44 is strongly associated with increased sensitivity to venetoclax in ex vivo drug sensitivity studies.45 Venetoclax in combination with azacitidine eliminates leukemic stem cells by inhibiting mitochondrial electron transport chain complex II activity.46 Two studies have shown that inhibition of mitochondrial function sensitizes AML cells to venetoclax.47,48 Studies in mice and cell lines have demonstrated that mutant NPM1 impairs mitochondrial function, a likely mechanism for the exquisite sensitivity of NPM1-mutated cells to venetoclax.48 Venetoclax/azacitidine induced a morphologic response in six of eight children with MDS or AML; three were MRD-negative.49 To our knowledge, the use of venetoclax/azacitidine to achieve a deep remission in MDS/AML in FA or DCL has not been reported. AML is distinguished from MDS on the basis of a BM blast cutoff of >20%. Several myeloid neoplasms are classified as AML on the basis of the presence of an AML-defining genomic aberration [eg, t(8; 21)], regardless of the blast percentage. In the current WHO classification, NPM1 mutation is not adequate for the diagnosis of AML when the blast percentage is below 20%. However, several studies suggest rapid progression to AML and a need for intensive AML-type therapy in MDS with NPM1 mutations, raising the question of whether NPM1-mutated MDS should be classified as AML.50 Since MDS with excess blasts and AML are a continuum and NPM1-mutated MDS tends to rapidly progress to AML, we considered our patient to have MDS/AML and used an AML-type approach to achieve a deep remission before HSCT. In conclusion, we report a unique scenario of NPM1-mutated DCL in a patient with FA where MRD-negative remission with limited toxicity was achieved using venetoclax/azacitidine before HSCT, and the patient remains disease-free for over a year after HSCT. This case suggests that venetoclax/azacitidine can induce a deep remission in children with NPM1-mutated myeloid DCL who cannot tolerate intense chemotherapy and may represent a useful approach in the setting of other DDR defects or telomere diseases (eg, dyskeratosis congenita) that are characterized by poor chemotherapy tolerance; these patients often undergo HSCT for BM failure and are thereby at risk for DCL.3,51 Studies such as the ongoing multicenter trial (ClinicalTrials.gov identifier: NCT05292664) of venetoclax/azacitidine are needed to investigate the outcomes and optimal dosing for this regimen in FA. PRIOR PRESENTATION SUPPORT AUTHOR CONTRIBUTIONS Conception and design: Julie Ma, Michael A. Pulsipher, Chintan Parekh Provision of study materials or patients: Kenji Morimoto, Michael A. Pulsipher Collection and assembly of data: Julie Ma, Kenji Morimoto, Chintan Parekh Data analysis and interpretation: All authors Manuscript writing: All authors Final approval of manuscript: All authors Accountable for all aspects of the work: All authors AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Presented as a poster presentation at the American Society of Pediatric Hematology/Oncology, Philadelphia, PA, May 4-7, 2022. M.A.P. was supported by 1U01AI126612-01A1, P30CA040214, and 2UG1HL069254. Michael A. Pulsipher Honoraria: Novartis Consulting or Advisory Role: Novartis, Medexus Pharmaceuticals, Equillium, GentiBio, Vertex, Bluebird Bio Research Funding: Adaptive Biotechnologies, Miltenyi Biotec Chintan Parekh Consulting or Advisory Role: Appia Bio Patents, Royalties, Other Intellectual Property: Pluto Immunotherapeutics Other Relationship: Amgen, Pluto Immunotherapeutics No other potential conflicts of interest were reported. Michael A. Pulsipher Honoraria: Novartis Consulting or Advisory Role: Novartis, Medexus Pharmaceuticals, Equillium, GentiBio, Vertex, Bluebird Bio Research Funding: Adaptive Biotechnologies, Miltenyi Biotec Chintan Parekh Consulting or Advisory Role: Appia Bio Patents, Royalties, Other Intellectual Property: Pluto Immunotherapeutics Other Relationship: Amgen, Pluto Immunotherapeutics No other potential conflicts of interest were reported. ==== Refs REFERENCES 1. Alter BP Giri N Savage SA et al Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up Haematologica 103 30 39 2018 29051281 2. Dufour C How I manage patients with Fanconi anaemia Br J Haematol 178 32 47 2017 28474441 3. Shimamura A Alter BP Pathophysiology and management of inherited bone marrow failure syndromes Blood Rev 24 101 122 2010 20417588 4. Tischkowitz MD Hodgson SV Fanconi anaemia J Med Genet 40 1 10 2003 12525534 5. Mitchell R Wagner JE Hirsch B et al Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia Br J Haematol 164 384 395 2014 24172081 6. Alter BP Fanconi anemia and the development of leukemia Best Pract Res Clin Haematol 27 214 221 2014 25455269 7. Ebens CL MacMillan ML Wagner JE Hematopoietic cell transplantation in Fanconi anemia: Current evidence, challenges and recommendations Expert Rev Hematol 10 81 97 2017 27929686 8. Gluckman E Devergie A Schaison G et al Bone marrow transplantation in Fanconi anaemia Br J Haematol 45 557 564 1980 7000153 9. Guardiola P Socié G Li X et al Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: Risk factors and influence on outcome Blood 103 73 77 2004 12946993 10. Peffault de Latour R Porcher R Dalle JH et al Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: The European Group for Blood and Marrow Transplantation experience Blood 122 4279 4286 2013 24144640 11. Deeg HJ Socié G Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients Blood 87 386 392 1996 8547667 12. Rosenberg PS Socié G Alter BP et al Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants Blood 105 67 73 2005 15331448 13. Peffault de Latour R Soulier J How I treat MDS and AML in Fanconi anemia Blood 127 2971 2979 2016 27020090 14. Aldoss I Clark M Marcucci G et al Donor derived leukemia in allogeneic transplantation Leuk Lymphoma 62 2823 2830 2021 34713775 15. Shiozaki H Yoshinaga K Kondo T et al Donor cell-derived leukemia after cord blood transplantation and a review of the literature: Differences between cord blood and BM as the transplant source Bone Marrow Transpl 49 102 109 2014 16. Wiseman DH Donor cell leukemia: A review Biol Blood Marrow Transplant 17 771 789 2011 20951819 17. Aldoss I Song JY Curtin PT et al Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy Blood Adv 4 4798 4801 2020 33022063 18. Williams L Doucette K Karp JE et al Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome Bone Marrow Transpl 56 1535 1549 2021 19. Falini B Sciabolacci S Falini L et al Diagnostic and therapeutic pitfalls in NPM1-mutated AML: Notes from the field Leukemia 35 3113 3126 2021 33879827 20. Hiemenz MC Ostrow DG Busse TM et al OncoKids: A comprehensive next-generation sequencing panel for pediatric malignancies J Mol Diagn 20 765 776 2018 30138724 21. Bitan M Or R Shapira MY et al Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors Biol Blood Marrow Transplant 12 712 718 2006 16785060 22. MacMillan ML Wagner JE Haematopoeitic cell transplantation for Fanconi anaemia—When and how? Br J Haematol 149 14 21 2010 20136826 23. MacMillan ML DeFor TE Young JA et al Alternative donor hematopoietic cell transplantation for Fanconi anemia Blood 125 3798 3804 2015 25824692 24. Shimada A Takahashi Y Muramatsu H et al Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen Int J Hematol 95 675 679 2012 22527854 25. Stepensky P Shapira MY Balashov D et al Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning Biol Blood Marrow Transplant 17 1282 1288 2011 21220033 26. Walter RB Gooley TA Wood BL et al Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia J Clin Oncol 29 1190 1197 2011 21282535 27. DiNardo CD Tiong IS Quaglieri A et al Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML Blood 135 791 803 2020 31932844 28. Pratz KW Jonas BA Pullarkat V et al Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine J Clin Oncol 40 855 865 2022 34910556 29. Tiong IS Dillon R Ivey A et al Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia Br J Haematol 192 1026 1030 2021 32458446 30. DiNardo CD Maiti A Rausch CR et al 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: A single-centre, phase 2 trial Lancet Haematol 7 e724 e736 2020 32896301 31. Richard-Carpentier G DiNardo CD Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy Ther Adv Hematol 10 204062071988282 2019 32. Venclexta (venetoclax) [US prescribing information] North Chicago, IL AbbVie 2016 33. Agarwal SK DiNardo CD Potluri J et al Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: Evaluation of dose adjustments Clin Ther 39 359 367 2017 28161120 34. Bhatnagar S Mukherjee D Salem AH et al Dose adjustment of venetoclax when co-administered with posaconazole: Clinical drug-drug interaction predictions using a PBPK approach Cancer Chemother Pharmacol 87 465 474 2021 33398386 35. Aiba M Shigematsu A Suzuki T et al Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia Ann Hematol 102 541 546 2023 36646889 36. Hertenstein B Hambach L Bacigalupo A et al Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT) Haematologica 90 969 975 2005 15996934 37. Mehta PA Ileri T Harris RE et al Chemotherapy for myeloid malignancy in children with Fanconi anemia Pediatr Blood Cancer 48 668 672 2007 16609946 38. Talbot A de Latour RP Raffoux E et al Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia Haematologica 99 e199 e200 2014 25085358 39. Samra B Konopleva M Isidori A et al Venetoclax-based combinations in acute myeloid leukemia: Current evidence and future directions Front Oncol 10 562558 2020 33251134 40. Jin S Cojocari D Purkal JJ et al 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis Clin Cancer Res 26 3371 3383 2020 32054729 41. DiNardo CD Pratz K Pullarkat V et al Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia Blood 133 7 17 2019 30361262 42. Pollyea DA Pratz K Letai A et al Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study Am J Hematol 96 208 217 2021 33119898 43. Bisaillon R Moison C Thiollier C et al Genetic characterization of ABT-199 sensitivity in human AML Leukemia 34 63 74 2020 31300747 44. Brunetti L Gundry MC Sorcini D et al Mutant NPM1 maintains the leukemic state through HOX expression Cancer Cell 34 499 512.e9 2018 e9,30205049 45. Kontro M Kumar A Majumder MM et al HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia Leukemia 31 301 309 2017 27499136 46. Pollyea DA Stevens BM Jones CL et al Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia Nat Med 24 1859 1866 2018 30420752 47. Sharon D Cathelin S Mirali S et al Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response Sci Transl Med 11 eaax2863 2019 31666400 48. Wu HC Rerolle D Berthier C et al Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy Cancer Discov 11 3198 3213 2021 34301789 49. Winters AC Maloney KW Treece AL et al Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia Pediatr Blood Cancer 67 e28398 2020 32735397 50. Forghieri F Nasillo V Paolini A et al NPM1-Mutated myeloid neoplasms with <20% blasts: A really distinct clinico-pathologic entity? Int J Mol Sci 21 8975 2020 33255988 51. Fioredda F Iacobelli S Korthof ET et al Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita Br J Haematol 183 110 118 2018 29984823